Alpspitz Bioscience
Private Company
Funding information not available
Overview
Alpspitz Bioscience is an early-stage diagnostics company targeting the massive global burden of cardiovascular diseases (CVDs). Its core innovation is the DefenceDX platform, a saliva test that uses AI to analyze inflammatory biomarkers, aiming to provide an easy-to-use, preventative screening tool for CVD risk. The company positions itself in the digital health and preventative diagnostics space, seeking partnerships to advance and commercialize its technology.
Technology Platform
DefenceDX: A saliva-based diagnostic platform combining AI for biomarker recognition, immunology to detect inflammation, and blockchain for data security. Aims to provide non-invasive screening for cardiovascular disease risk.
Opportunities
Risk Factors
Competitive Landscape
Competes with established blood-based lab tests for inflammatory markers (e.g., hs-CRP), advanced imaging for coronary calcium, and genetic risk scores. Also faces competition from a growing field of digital health startups developing AI-powered diagnostic and risk assessment tools, though a focused saliva-based CVD test may be a niche differentiator.